ECS Botanics Holdings (ASX:ECS) reported revenue of AU$4.9 million in the fiscal second quarter ended Dec. 31, 2024, down 33% on the year-ago period, according to a Tuesday filing with the Australian bourse.
The medicinal cannabis company attributed the decline to customers' shift from medicinal cannabis oils to other dosage forms and the delayed effect of its strategic transition to the business-to-consumer model, which it is implementing in response to changing preferences.
ECS Botanics logged cash receipts of AU$4.7 million, down 28% year on year, the filing said.
It expects to generate positive cash flow within the next six months as a result of its transition to the B2C model.
ECS Botanics' shares rose 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.